20 articles
Expert reviews rank fisetin and quercetin as top senolytics, with spermidine and resveratrol as supporting players in longevity supplement stacks.
Expert reviews compare leading senolytic and NAD+ supplement brands on ingredients, evidence quality, and value.
A product review breaks down the evidence tiers for four popular longevity supplements and rates the best commercial stacks.
A Cochrane meta-analysis of 8 RCTs finds most pharmacological treatments fail to improve ataxia scores, though upper limb dexterity may benefit.
A Cochrane review of two RCTs finds very low-certainty evidence that IGF-1 neither prevents nor worsens retinopathy of prematurity in extremely preterm infants.
New review reveals how senescent cells both prevent and promote cancer, opening therapeutic opportunities.
A Cochrane meta-analysis of 11 RCTs finds very low-certainty evidence that liver support systems neither reduce mortality nor improve key outcomes in ALF.
A new Cell Metabolism review from NIH identifies how ECM stiffening, poor blood flow, and mitochondrial failure lock tissues into accelerating decline.
A comparative review of NMN and NR supplements weighs tissue targeting, clinical evidence, and top-rated products for NAD+ optimization.
A new review maps the bidirectional crosstalk between gut microbiota and cellular senescence driving multi-organ degeneration.
A candid breakdown of top NAD+ booster brands reveals strong biomarker data but slim evidence for real longevity outcomes.
Researchers outline innovative approaches to speed up drug development for age-related diseases and longevity interventions.
A Cochrane review of 37 RCTs finds obesity drugs modestly reduce weight in adolescents, but evidence quality is low and long-term data are absent.
Expert reviews confirm NR and NMN raise blood NAD+, but longevity proof remains elusive and product quality varies widely.
New expert reviews compare NMN and NR head-to-head, ranking top products by purity, absorption, and clinical evidence.
Expert reviews compare NMN and NR head-to-head. NMN edges out for muscle and sleep benefits; NR leads for neuroprotection.
A rigorous product review reveals major quality gaps in NAD+ supplements and what dosing evidence actually supports.
A Cochrane meta-analysis of 17 RCTs finds amyloid-targeting antibodies offer minimal cognitive gains while significantly raising ARIA risk.
Fusobacterium nucleatum has shifted from suspected bystander to confirmed cancer driver — here's what the science reveals.
A 2026 comparative review of leading NAD+ supplements reveals NR has stronger human data, while NMN marketing often outpaces clinical proof.
